Enfortumab vedotin and radiation for bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of a targeted drug (enfortumab vedotin) and focused radiation before surgery to remove the bladder. It aims to improve outcomes for people with bladder cancer that has not spread beyond the bladder.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have bladder cancer that has grown into the bladder wall but has not spread to lymph nodes or other organs (stage T1–T4a, N0, M0).
- You must be scheduled for surgery to remove the bladder (radical cystectomy).
- Your cancer must be a type called urothelial carcinoma, though it may have some variant features (like squamous or glandular) as long as it is not entirely variant and has no small-cell or neuroendocrine parts.
- You must be 18 years or older.
- You must have a good performance status (ECOG 0–1), meaning you are fully active or only limited in physically strenuous activities.
- Your blood counts, liver, and kidney function must be within acceptable limits (e.g., adequate white blood cells, platelets, hemoglobin, bilirubin, and liver enzymes).
- You must not have had prior systemic therapy for bladder cancer (except BCG or other bladder instillations for non-muscle-invasive disease), prior pelvic radiation, or any other investigational treatment for this cancer.
- You must not have significant nerve damage (neuropathy) of grade 2 or higher, active infections, heart problems, or other uncontrolled illnesses.
- Women must not be pregnant or nursing, and both men and women must agree to use effective birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This Phase 1/2 trial tests whether combining sacituzumab govitecan with enfortumab vedotin (and in one group, pembrolizumab) can shrink or control metastatic urothelial (bladder/urinary tract) cancer. It’s mainly for people whose cancer has grown despite prior treatment.
This trial tests a drug called enfortumab vedotin combined with radiation therapy for people with locally advanced bladder cancer that hasn't spread to distant organs. The goal is to see if this combination works better than radiation alone and helps control the cancer.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to see if they can control muscle-invasive bladder cancer without needing to remove the bladder. It may be an option for people who want to try to preserve their bladder and avoid surgery or radiation.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.